

Notice under section 708AA(2)(f) of the *Corporations Act 2001 (Cth)*

15 July 2026

This notice is given by Starpharma Holdings Limited (ACN 078 532 180) (ASX: SPL, US OTC: SPHRY) (**Company**) under section 708AA(2)(f) of the *Corporations Act 2001 (Cth)* (**Corporations Act**) as modified by *ASIC Corporations (Non-Traditional Rights Issues) Instrument 2026/98*.

On 15 July 2026, the Company announced a fully underwritten renounceable pro-rata entitlement offer (**Entitlement Offer**) to eligible shareholders with a registered address in Australia, New Zealand, Hong Kong, Singapore, the United Kingdom and Luxembourg (**Eligible Shareholders**) of 1 new fully paid ordinary share in the Company (**New Share**) for every 7.5 fully paid ordinary shares in the Company at an offer price of \$0.57 per New Share. The Company is seeking to raise approximately \$32 million under the Entitlement Offer. The Entitlement Offer includes a facility to allow Eligible Shareholders to subscribe for additional New Shares (up to 100% of their pro-rata entitlement) (**Oversubscription Facility**).

Further details regarding the Entitlement Offer are set out in the ASX announcement accompanying this notice and will be included in the Company's Offer Booklet to be despatched to Eligible Shareholders on 23 July 2026.

The Company confirms that:

- (a) The New Shares will be offered under the Entitlement Offer without disclosure to investors under Part 6D.2 of the Corporations Act.
- (b) This notice is being given under section 708AA(2)(f) of the Corporations Act.
- (c) As at the date of this notice, the Company has complied with:
 - (1) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (2) section 674 and section 674A of the Corporations Act.
- (d) As at the date of this notice, there is no 'excluded information' of the type referred to in section 708AA(8) or section 708AA(9) of the Corporations Act that is required to be set out in this notice under section 708AA(7) of the Corporations Act.
- (e) The potential effect that the Entitlement Offer will have on the control of the Company and the consequences of that effect will depend on a number of factors, including the extent to which Eligible Shareholders take up their entitlements under the Entitlement Offer.

As the Entitlement Offer is structured as a fully underwritten pro-rata issue, and having regard to the current level of substantial holdings in the Company (based on substantial holding notices lodged on or before the date of this notice), the Entitlement Offer is not expected to have any material effect or consequence on the control of the Company.

The potential effect that the issue of New Shares under the Entitlement Offer will have on control, and the consequences of that effect, are as follows:

- (1) If an Eligible Shareholder takes up their entitlements under the Entitlement Offer, they will maintain their existing percentage interest in the total issued



capital of the Company. Eligible Shareholders who apply for additional New Shares under the Oversubscription Facility may increase their percentage interest in the total issued capital of the Company.

- (2) If an Eligible Shareholder does not take up all of their entitlements under the Entitlement Offer, their percentage interest in the total issued capital of the Company will be diluted.
- (3) If a shareholder is not an Eligible Shareholder, they will not be entitled to participate in the Entitlement Offer and their percentage interest in the total issued capital of the Company will be diluted.
- (4) The Entitlement Offer is fully underwritten by Canaccord Genuity (Australia) Limited ACN 075 071 466 (**Lead Manager**). To the extent there is a shortfall under the Entitlement Offer, the shortfall New Shares will be allocated to the Lead Manager and sub-underwriters. The issue of any New Shares to the Lead Manager or any sub-underwriter is not expected to have any material effect on the control of the Company.

About Starpharma

Starpharma (ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of our unique dendrimer technology.

Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties—including their size, structure, high degree of branching, polyvalency, and water solubility—are advantageous in medical and pharmaceutical applications.

Starpharma's portfolio of dendrimer-based products includes clinical-stage DEP® (dendrimer enhanced product) assets, preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products.

For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on [LinkedIn](#).

Investor & Media Relations

Gabriella Hold
gaby@thecapitalnetwork.com.au

Starpharma Holdings Limited

Cheryl Maley, Chief Executive Officer
Justin Cahill, Chief Financial and Operations Officer and
Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford VIC 3067

Disclosure

This ASX Announcement was
authorised for release by the Chair,
Mr Rob Thomas.

Forward-Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document, nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.